Business

Johnson & Johnson and Goldman sneeze, and stocks catch a cold

US stocks fell Tuesday after weak first-quarter reports from Johnson & Johnson and Goldman Sachs frustrated investors. Health care companies lost the most.

Wall Street has high hopes for company earnings this spring, and weak results from the world’s largest health care products company and one of the biggest financial firms had them concerned. Johnson & Johnson took its biggest one-day loss in a year.

Advertisement

Investors also looked for safety after the British government called for a surprise early election next month. Bond prices and the pound rose, and European stock indexes tumbled.

Kate Warne, an investment strategist for Edward Jones, said Goldman Sachs and Johnson & Johnson had a dramatic effect on stocks because investors expect a very strong round of company earnings reports this month. According to S&P Global Markets Intelligence, investors expect first-quarter earnings for S&P 500 companies to rise almost 10 percent, compared to last year. That would be the biggest jump since 2014.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

‘‘The reason it’s so important is that the stronger growth is likely to support higher stock prices even in the absence of pro-growth policies from the Trump administration,’’ she said.

The Standard & Poor’s 500 index shed 0.3 percent, to 2,342.19. The Dow Jones industrial average lost 0.6 percent, to 20,523.28. Goldman Sachs was responsible for most of that loss.

The Nasdaq composite fell 0.1 percent, to 5,849.47. The Russell 2000 index of small-company stocks recovered from an early loss and rose nearly 0.1 percent, to 1,361.89.

Advertisement

On Monday, stocks made their biggest gains in six weeks. But over the last few weeks they’ve mostly drifted lower, while bond yields have fallen to five-month lows.

Johnson & Johnson’s revenue from its biggest-selling drug, the Crohn’s disease treatment Remicade, fell 6 percent. Meanwhile, growth for many consumer health products slowed, and payers demanded bigger rebates on treatments for cardiovascular ailments, diabetes, and primary care products. The maker of Tylenol and Band-Aids lost 3.1 percent.

Prescription drug distributor Cardinal Health also dropped after it gave weak profit forecasts for this year and next as drug prices continue to fall. It will also pay $6.1 billion to buy a group of businesses from medical device maker Medtronic. Cardinal Health sank 11.5 percent. Competitors AmerisourceBergen and McKesson each fell about 5 percent.

Goldman Sachs’s revenue fell short of investor projections; its highly regarded trading desks didn’t perform as well as their competitors. The stock gave up 4.7 percent, its biggest loss since June. The stock reached all-time highs above $250 a share in March.

As investors snapped up government bonds, their prices jumped. The yield on the 10-year Treasury note fell to 2.18 percent, its lowest since Nov. 11. It finished at 2.25 percent Monday.

Investors also bought shares of companies that pay big dividends. Household goods makers like Kraft Heinz and Molson Coors, along with utilities, real estate investment trusts, and phone companies finished higher.

Netflix sagged after it didn’t gain as many subscribers in the first quarter as investors hoped. Its second-quarter profit guidance also fell short of analyst estimates. Netflix stock lost 2.6 percent.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.